share_log

6-K: Gsk on track to deliver 2024 outlooks with further good progress made in r&d

6-K: Gsk on track to deliver 2024 outlooks with further good progress made in r&d

6-K：葛兰素史克有望实现2024年愿景，研发方面取得进一步良好进展
美股SEC公告 ·  2024/10/30 23:27

Moomoo AI 已提取核心信息

GSK reported Q3 2024 total sales of £8.0 billion, down 2% AER but up 2% CER, driven by strong Specialty Medicines performance offsetting lower Vaccines sales. Core operating profit grew 5% CER to £2.8 billion, reflecting favorable product mix and cost management.Total operating profit fell 86% to £189 million after a £1.8 billion charge for Zantac settlement, covering 93% of US state court cases. Core EPS increased 5% CER to 49.7p, while reported EPS was -1.4p. The company reached agreements to resolve approximately 80,000 Zantac cases for up to $2.2 billion.GSK confirmed its full-year 2024 guidance, expecting to deliver around the middle of ranges: 7-9% sales growth, 11-13% core operating profit growth, and 10-12% core EPS growth at CER. Q3 dividend of 15p declared, with full-year dividend expected at 60p. The company made further R&D progress with 11 positive phase III trials reported year-to-date.
GSK reported Q3 2024 total sales of £8.0 billion, down 2% AER but up 2% CER, driven by strong Specialty Medicines performance offsetting lower Vaccines sales. Core operating profit grew 5% CER to £2.8 billion, reflecting favorable product mix and cost management.Total operating profit fell 86% to £189 million after a £1.8 billion charge for Zantac settlement, covering 93% of US state court cases. Core EPS increased 5% CER to 49.7p, while reported EPS was -1.4p. The company reached agreements to resolve approximately 80,000 Zantac cases for up to $2.2 billion.GSK confirmed its full-year 2024 guidance, expecting to deliver around the middle of ranges: 7-9% sales growth, 11-13% core operating profit growth, and 10-12% core EPS growth at CER. Q3 dividend of 15p declared, with full-year dividend expected at 60p. The company made further R&D progress with 11 positive phase III trials reported year-to-date.
GSk报告2024财年第三季度总销售额为80亿英镑，同比下降2%（按实际汇率计算），但按恒定汇率增长2%，主要得益于强劲的特殊药物表现，抵消了疫苗销售的下降。核心营业利润按恒定汇率增长5%，达28亿英镑，反映了有利的产品组合和成本管理。总营业利润下降86%，至18900万英镑，因Zantac和解计入了18亿英镑的费用，涵盖了93%的美国州法院案件。核心每股收益按恒定汇率增加5%，至49.7便士，而报告每股收益为-1.4便士。该公司已达成协议，解决大约80,000个Zantac案件，达成最高22亿美金的和解。GSk确认了2024财年的全年指引，预计销售增长和核心营业利润增长均约在范围中间：销售增长7-9%，核心营业利润增长11-13%，核心每股收益增长10-12%（按恒定汇率计算）。宣布第三季度股息为15便士，全年股息预计为60便士。该公司在研发方面取得了进一步进展，今年迄今报告了11个积极的第III阶段临床试验。
GSk报告2024财年第三季度总销售额为80亿英镑，同比下降2%（按实际汇率计算），但按恒定汇率增长2%，主要得益于强劲的特殊药物表现，抵消了疫苗销售的下降。核心营业利润按恒定汇率增长5%，达28亿英镑，反映了有利的产品组合和成本管理。总营业利润下降86%，至18900万英镑，因Zantac和解计入了18亿英镑的费用，涵盖了93%的美国州法院案件。核心每股收益按恒定汇率增加5%，至49.7便士，而报告每股收益为-1.4便士。该公司已达成协议，解决大约80,000个Zantac案件，达成最高22亿美金的和解。GSk确认了2024财年的全年指引，预计销售增长和核心营业利润增长均约在范围中间：销售增长7-9%，核心营业利润增长11-13%，核心每股收益增长10-12%（按恒定汇率计算）。宣布第三季度股息为15便士，全年股息预计为60便士。该公司在研发方面取得了进一步进展，今年迄今报告了11个积极的第III阶段临床试验。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    施贵宝
    BMY
    -- 60.020
    默沙东
    MRK
    -- 89.230
    赛诺菲安万特
    SNY
    -- 55.820
    阿斯利康
    AZN
    -- 73.790
    艾伯维公司
    ABBV
    -- 205.290
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    FOMC维持利率但不确定性高企：美股后市走向如何？
    🎙️讨论 1. 美联储强调政策路径存在“高度不确定性”，你更关注利率预期变化还是经济数据对市场的短期影响？ 2. 若核心通胀维持高位，哪类板块更具交易机会——防御型股票还是科技成长股？ 展开
    联邦公开市场委员会新闻发布会，2025年3月19日